Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 26INDUSTRY 2NETWORK 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Fatigue 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Methylphenidate × Clear all
NCT01202734 2014-05-16

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
10 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

NCT00758407 2010-01-13

EMF

Medice Arzneimittel Pütter GmbH & Co KG

Phase 2/3 Completed
66 enrolled

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡